EGFR and lung adenocarcinoma: However, this has also brought a great challenge to routine pathology, as approximately 64% of lung adenocarcinomas harbour at least one somatic oncogenic mutations in EGFR, HER2, KRAS, PIK3CA, BRAF, MEK1, and ALK10, 11.